Cefprozil

Mechanism :

Cefprozil is a semisynthetic broad-spectrum cephalosporin antibiotic intended for oral administration. It has in vitro activity against a broad range of gram positive and gram-negative bacteria. The bactericidal action of cefprozil results from inhibition of cell-wall synthesis.

Indication :

• Pharyngitis/tonsillitis
• Otitis media
• Acute sinusitis
• Uncomplicated skin and soft tissue infections

Contraindications :

In patients with known allergy to the cephalosporin class of antibiotics or to any component of the cefprozil preparations.

Dosing :

Adverse Effect :

Diarrhea, nausea, vomiting, abdominal pain, pseudomembranous colitis, elevations of AST/ALT, alkaline phosphatase, bilirubin, hypersensitivity (rash, urticaria, anaphylaxis, angioedema), serum-sickness like reactions, Stevens-Johnson syndrome, dizziness, hyperactivity, headache, insomnia, decreased leukocyte count, eosinophilia, elevated BUN, serum creatinine, thrombocytopenia.

Interaction :

Aminoglycoside and cephalosporin antibiotics: Nephrotoxicity has been reported following concomitant administration of aminoglycoside antibiotics and cephalosporin antibiotics.
Probenecid: Concomitant administration of probenecid doubled the AUC for cefprozil.

The bioavailability of the capsule formulation of cefprozil was not affected when administered 5 minutes following an antacid.
Drug/Laboratory Test Interactions: Cephalosporin antibiotics may produce a false positive reaction for glucose in the urine with copper reduction tests (Benedict's or Fehling's solution or with Clinitest tablets), but not with enzyme-based tests for glycosuria. A false negative reaction may occur in the ferricyanide test for blood glucose. The presence of cefprozil in the blood does not interfere with the assay of plasma or urine creatinine by the alkaline picrate method.

Hepatic Dose :